GBS to be listed rare side effect of J&J vaccine - EMA

Thursday, 22. July 2021 16:28

European Medicines Agency released a statement on Thursday announcing that Guillain-Barré syndrome (GBS) will be listed as a rare side effect of the COVID-19 vaccine Janssen produced by Johnson & Johnson. The decision has been made after EMA's safety committee looked into 108 GBS cases since June 30, out of a total of 21 million people worldwide who received the jab.

GBS is a neurological disorder, which in severe cases can progress to paralysis, but most patients fully recover from it. Out of the GBS cases related to the Janssen vaccine, only one death has been reported. EMA reiterated that the benefits of getting vaccinated still outweigh the risks.

The warning against GBS will also be included with the AstraZeneca Vaxzevria vaccine. However, no connection was found between the occurrence of the syndrome and the Comirnaty and Spikevax vaccines, previously known as COVID-19 Vaccine Moderna.

Related Links: Johnson & JohnsonAstraZeneca plc
Breaking the News / LH